Skip to main content
. 2020 Apr 16;10(4):e033482. doi: 10.1136/bmjopen-2019-033482

Table 1.

Baseline demographics of the patient cohort presenting to the ED for AF-related reasons, stratified by appropriateness of visit

All patients Assessed as appropriate Assessed as inappropriate
n=356 n=85 n=271 P value
Age (mean±SD) 67±13 67±14 67±13 NS
Female (n (%)) 160 (45) 40 (47) 120 (44) NS
Duration of AF from time of initial diagnosis in months (mean±SD) 14 (±9) 15 (±10) 14 (±9) NS
Type of AF (n (%))
 Paroxysmal 245 (69) 56 (66) 189 (70) NS
 Persistent 40 (11) 11 (13) 29 (11) NS
 Permanent 71 (20) 18 (21) 53 (19) NS
Comorbidities (n (%))
 CHF 34 (10) 15 (18) 19 (7) p=0.007
 HTN 164 (46) 41 (48) 123 (45) NS
 DM 38 (11) 10 (12) 28 (10) NS
 Stroke/TIA 35 (10) 10 (12) 25 (9) NS
 MIPADAP 37 (10) 14 (16) 23 (9) p=0.04
CHADS2-VASc score (n (%))
 0 56 (16) 10 (12) 46 (17) NS
 1 54 (15) 18 (21) 36 (13) NS
 ≥2 242 (68) 55 (65) 187 (69) NS
Medications (n (%))
 CC-blocker 72 (20) 17 (20) 55 (20.3) NS
 ß-blocker 170 (48) 40 (47) 130 (48) NS
 ARB 26 (7) 8 (9) 18 (6.6) NS
 ACE-I 47 (13) 11 (13) 36 (13) NS
 AAD 90 (25) 26 (31) 64 (24) NS
 ASA 68 (19) 21 (25) 47 (17) NS
 DOAC 166 (46) 38 (45) 128 (48) NS
 Warfarin 45 (13) 17 (20) 28 (10 p=0.03
 OAC 211 (59) 55 (65) 156 (58) NS
 Duration of AF before ED visit in minutes (n, mean±SD) 717.1±332 773.7±301 699.2±340 NS
Thirty-day symptoms (n (%))*
 Yes 241 (68) 62 (73) 179 (66) NS
 No 114 (32) 23 (27) 91 (34) NS
Previous ED Visits (n (%))
 0 31 (9) 10 (12) 21 (8) NS
 1 82 (23) 17 (20) 65 (24) NS
 2 61 (17) 11 (13) 50 (19) NS
 3 47 (13) 15 (18) 32 (12) NS
 4 22 (6) 4 (5) 18 (7) NS
 5 111 (31) 28 (33) 83 (31) NS
ED visit every AF episode (n (%))
 Yes 94 (27) 24 (28) 70 (26) NS
 No 149 (42) 34 (40) 115 (42) NS

*Symptoms with the 30 days preceding ED attendance related to AF.

AAD, antiarrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AF, atrial fibrillation; ARB, Angiotensin II receptor blocker; ASA, aspirin; CC-blocker, calcium-channel blocker; CHF, congestive heart failure; DM, diabetes mellitus; DOAC, direct oral anticoagulant; ED, emergency department; HTN, hypertension; MIPADAP, myocardial infarction with peripheral arterial disease; OAC, oral anticoagulant; TIA, transient ischaemic attack.